Mechanism of Action
ActRII/Smad Signaling
Activin binds type II receptors (ActRIIA or ActRIIB), which transphosphorylate type I receptors (ALK4/5), activating Smad2/3 signaling. Smad2/3 complex with Smad4 translocates to the nucleus to regulate gene expression. In muscle: Smad2/3 suppresses mTORC1, promotes atrophy genes. In bone marrow: Smad2/3 suppresses late-stage erythroid differentiation. In pituitary: activin stimulates FSH-beta transcription. In cancer: Smad2/3 promotes TGF-beta tumor suppressor gene programs in early stage but may facilitate EMT in later stages.
Inhibin and Follistatin Counterregulation
The activin system is tightly regulated by inhibin (heterodimer of alpha-subunit with beta-A or beta-B) and follistatin. Inhibin acts as a competitive antagonist for ActRII binding. Follistatin binds activin directly, preventing receptor access. This three-way balance (activin/inhibin/follistatin) governs FSH secretion during the menstrual cycle and regulates the intensity of activin signaling in peripheral tissues.
Research Summary
Pulmonary Arterial Hypertension (Sotatercept)
FDA Approved (Antagonist)Sotatercept (ActRIIA-Fc) FDA-approved 2024 for PAH: STELLAR trial showed 84.9% improvement in 6-minute walk distance vs 25% placebo, with significant reductions in pulmonary vascular resistance. The activated anti-proliferative bone morphogenic protein pathway and reduced activin-A-driven vascular smooth muscle proliferation are proposed mechanisms.
Anemia (Luspatercept)
FDA Approved (Antagonist)Luspatercept (ActRIIB-Fc ligand trap) FDA-approved for anemia in beta-thalassemia and lower-risk MDS. Trapping activin B and GDF11 (which inhibit late erythroid differentiation) promotes maturation of late-stage erythroid progenitors, increasing red blood cell production without EPO stimulation.
Muscle Cachexia
Phase 2/3Bimagrumab (anti-ActRIIB antibody) blocks activin and myostatin signaling, dramatically increasing lean mass in sarcopenia and cancer cachexia trials. Phase 3 data in obesity showed 21% lean mass gain and 20% fat mass reduction. Phase 2/3 programs ongoing for muscle-wasting conditions.
Calculate your Activin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| FSH regulation research | 1-10 mcg/kg IV in pituitary-intact animal models | Per session | Intravenous |
| Muscle/bone research | 5-50 mcg/kg SC 2x/week in rodent models | 2x/week | Subcutaneous |
Research typically uses recombinant activin-A or activin-B as homodimers. Clinical interest focuses on antagonism (sotatercept, luspatercept, bimagrumab) rather than agonism.
Interactions
Safety Profile
Recombinant activin-A injection in research: expected FSH stimulation, muscle suppression, and pro-inflammatory effects at high doses. Chronic activin-A elevation is associated with anemia, cardiac hypertrophy, and inflammatory disease. Clinical evidence from sotatercept/luspatercept (activin pathway inhibitors): telangiectasia (sotatercept), thrombocytopenia, and dizziness are documented adverse effects. These are attributed to excess pathway inhibition, not activin agonism. Activin itself has no human pharmacology studies at therapeutic doses.
References
- [1]Vale W, et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature. 1986;321(6072):776-779.
- [2]Humbert M, et al. Sotatercept for the treatment of pulmonary arterial hypertension (STELLAR). N Engl J Med. 2023;388(13):1159-1171.